Drug Profile
Sabatolimab - Novartis Oncology
Alternative Names: AntiTIM-3 monoclonal antibody Novartis; MBG-453; NVP-MBG453Latest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Novartis
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Vaccines
- Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic myelomonocytic leukaemia
- Phase I/II Myelofibrosis; Solid tumours
- No development reported Glioblastoma
- Discontinued Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 31 Dec 2023 Discontinued - Phase-II for Myelodysplastic syndromes (Second-line therapy or greater) in USA (IV)
- 31 Dec 2023 Discontinued - Phase-I for Acute myeloid leukaemia (Combination therapy) in Singapore, Switzerland, Italy (IV)
- 31 Dec 2023 Discontinued - Phase-I for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Australia, USA, Finland, France, Germany, Netherlands, Spain, United Kingdom (IV)